Exploring the determinants that influence hospital costs of induction therapy for acute myeloid leukemia
- 16 April 2021
- journal article
- research article
- Published by Informa UK Limited in Leukemia & Lymphoma
- Vol. 62 (5), 1211-1218
- https://doi.org/10.1080/10428194.2020.1855339
Abstract
The financial burden of acute myeloid leukemia (AML) patients is substantial. We retrospectively analyzed the hospital costs of the first induction therapy for 353 newly diagnosed AML patients who were admitted to our hospital from January 2013 to December 2018. We found the median hospital costs were estimated at 110,291.8 RMB. Multivariate analysis showed that length of hospital stay was the leading determinant affecting hospital costs (p < 0.0001), followed by length of agranulocytosis days (p < 0.01), but for the patients who failed to achieve complete remission (CR), length of hospital stay was the independent factor contributing to hospital costs. Besides, patients achieving CR had similar hospital costs to the patients failing to achieve CR. The hospital costs of low-intensity chemotherapy might not be lower than that of intensive chemotherapy.Keywords
Funding Information
- National Natural Science Foundation of China (81770168)
This publication has 25 references indexed in Scilit:
- The global burden and attributable risk factor analysis of acute myeloid leukemia in 195 countries and territories from 1990 to 2017: estimates based on the global burden of disease study 2017Journal of Hematology & Oncology, 2020
- Economic and Clinical Burden of Relapsed and/or Refractory Active Treatment Episodes in Patients with Acute Myeloid Leukemia (AML) in the USA: A Retrospective Analysis of a Commercial Payer DatabaseAdvances in Therapy, 2019
- Healthcare expenses for treatment of acute myeloid leukemiaExpert Review of Hematology, 2019
- Acute myeloid leukaemiaThe Lancet, 2018
- Selecting initial treatment of acute myeloid leukaemia in older adultsBlood Reviews, 2017
- Diagnosis and management of AML in adults: 2017 ELN recommendations from an international expert panelBlood, 2017
- Continued improvement in survival of acute myeloid leukemia patients: an application of the loss in expectation of lifeBlood Cancer Journal, 2016
- Acute Myeloid Leukemia and Myelodysplastic Syndromes in Older AdultsJournal of Clinical Oncology, 2014
- Survival and cure of acute myeloid leukaemia in England, 1971‐2006: a population–based studyBritish Journal of Haematology, 2013
- The Economic Costs of Acute Myeloid Leukemia in SwedenInternational Journal of Technology Assessment in Health Care, 1994